Key result
Inflammatory biomarkers IL-6, IL-1β, and MDA were significantly higher in patients with ACS than healthy controls (p<0.05) and positively correlated with TIMI risk scores (r=0.53 to 0.68).
Why the study?
Inflammation plays a significant role in ACS pathophysiology but is not included in current risk stratification.
Do inflammatory biomarkers (IL-6, IL-1β, and MDA) correlate with the TIMI risk score in patients with acute coronary syndrome?
Cross-Sectional (n=91)
Do inflammatory biomarkers (IL-6, IL-1β, and MDA) correlate with the TIMI risk score in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Inflammatory biomarkers (IL-6, IL-1β, and MDA) are significantly elevated in ACS patients and correlate positively with the TIMI risk score, suggesting potential added prognostic value in risk stratification.
BACKGROUND: Inflammation plays a significant role in the pathophysiology of Acute Coronary Syndrome (ACS) but is not included in current risk stratification. OBJECTIVE: This study aimed at determining the association between Thrombolysis in Myocardial Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina (UA), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). We hypothesized that inflammatory biomarkers could add prognostic value to the TIMI risk score. METHODS: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA (malondialdehyde) were quantified by ELISA and colorimetry, respectively, of patients with ACS (n = 48; 31.3 % with UA, 33.3 % with NSTEMI, and 35.4 % with STEMI) and healthy controls (n = 43). We assessed the TIMI scores in the first 24 h after symptom onset. RESULTS: The results showed that patients with ACS had significantly higher levels (p<0.05) of the inflammatory biomarkers IL-6, IL-1β, and MDA than the control group. However, we found no significant differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI and IL-1β (r= 0.62) in STEMI patients. CONCLUSION: These data suggested the presence of a pro-inflammatory profile in patients with ACS as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β, and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining inflammatory biomarkers with the TIMI risk score could provide better insight into the processes involved in ACS.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2022) conducted a cross-sectional in Acute Coronary Syndrome (ACS) (n=91). Inflammatory biomarkers (IL-6, IL-1β, and MDA) vs. Healthy controls was evaluated on Correlation between TIMI risk score and inflammatory biomarkers (p=<0.05). Inflammatory biomarkers IL-6, IL-1β, and MDA were significantly higher in patients with ACS than healthy controls (p<0.05) and positively correlated with TIMI risk scores (r=0.53 to 0.68).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: